243 related articles for article (PubMed ID: 31623671)
21. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
22. Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.
Labourier E; Fahey TJ
Diagn Cytopathol; 2021 Apr; 49(4):E175-E180. PubMed ID: 33052631
[TBL] [Abstract][Full Text] [Related]
23. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
24. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
[TBL] [Abstract][Full Text] [Related]
25. Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
Choi SH; Baek JH; Lee JH; Choi YJ; Ha EJ; Song DE; Kim JK; Chung KW; Kim TY; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2016 Apr; 84(4):607-13. PubMed ID: 26215382
[TBL] [Abstract][Full Text] [Related]
26. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
Macerola E; Rago T; Proietti A; Basolo F; Vitti P
J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
[TBL] [Abstract][Full Text] [Related]
27. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
28. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
29. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
[TBL] [Abstract][Full Text] [Related]
30. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
[TBL] [Abstract][Full Text] [Related]
31. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
32. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
[TBL] [Abstract][Full Text] [Related]
33. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
34. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report.
Shrestha RT; Karunamurthy A; Amin K; Nikiforov YE; Caramori ML
Thyroid; 2015 Dec; 25(12):1375-8. PubMed ID: 26355276
[TBL] [Abstract][Full Text] [Related]
35. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
36. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
[TBL] [Abstract][Full Text] [Related]
37. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
[TBL] [Abstract][Full Text] [Related]
38. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.
Lubitz CC; Economopoulos KP; Pawlak AC; Lynch K; Dias-Santagata D; Faquin WC; Sadow PM
Thyroid; 2014 Jun; 24(6):958-65. PubMed ID: 24417340
[TBL] [Abstract][Full Text] [Related]
39. Expanding the Spectrum of
De Leo A; Serban D; Maloberti T; Sanza V; Coluccelli S; Altimari A; Gruppioni E; Chiarucci F; Corradini AG; Repaci A; Colapinto A; Nannini M; Pantaleo MA; de Biase D; Tallini G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835466
[TBL] [Abstract][Full Text] [Related]
40. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
